Evidence map›Paper›PMID 35054866›Full record

ArticleInternational journal of molecular sciences2022

Creating a Natural Vascular Scaffold by Photochemical Treatment of the Extracellular Matrix for Vascular Applications.

Katalin Kauser, Kevin S Warner, Blake Anderson, Edgar Dalles Keyes, R B Hayes, Eric Kawamoto, D H Perkins, Robert Scott, Jim Isaacson, Barb Haberer and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Katalin KauserAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.
Kevin S WarnerAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.ORCID 0000-0002-4350-1855
Blake AndersonAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.
Edgar Dalles KeyesDepartment of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT 84112, USA.
R B HayesAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.
Eric KawamotoAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.
D H PerkinsAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.
Robert ScottAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.ORCID 0000-0002-7786-5091
Jim IsaacsonAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.
Barb HabererAlumend, LLC, 4800 N. Career Avenue, Suite #108, Sioux Falls, SD 57107, USA.
Ann SpaansAlumend, LLC, 4800 N. Career Avenue, Suite #108, Sioux Falls, SD 57107, USA.
Ronald UtechtAlumend, LLC, 4800 N. Career Avenue, Suite #108, Sioux Falls, SD 57107, USA.
Hank HauserAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.
Andrew George RobertsDepartment of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT 84112, USA.ORCID 0000-0002-2221-534X
Myles GreenbergAlucent Biomedical Inc., 675 Arapeen Dr, Suite #102, Salt Lake City, UT 84108, USA.
University of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of bioscaffolds for cardiovascular medical applications, such as peripheral artery disease (PAD), remains to be a challenge for tissue engineering. PAD is an increasingly common and serious cardiovascular illness characterized by progressive atherosclerotic stenosis, resulting in decreased blood perfusion to the lower extremities. Percutaneous transluminal angioplasty and stent placement are routinely performed on these patients with suboptimal outcomes. Natural Vascular Scaffolding (NVS) is a novel treatment in the development for PAD, which offers an alternative to stenting by building on the natural structural constituents in the extracellular matrix (ECM) of the blood vessel wall. During NVS treatment, blood vessels are exposed to a photoactivatable small molecule (10-8-10 Dimer) delivered locally to the vessel wall via an angioplasty balloon. When activated with 450 nm wavelength light, this therapy induces the formation of covalent protein-protein crosslinks of the ECM proteins by a photochemical mechanism, creating a natural scaffold. This therapy has the potential to reduce the need for stent placement by maintaining a larger diameter post-angioplasty and minimizing elastic recoil. Experiments were conducted to elucidate the mechanism of action of NVS, including the molecular mechanism of light activation and the impact of NVS on the ECM.

Indexed as

Blood Vessel ProsthesisAngioplasty, BalloonAnimalsArteriesBiomechanical PhenomenaCross-Linking ReagentsDimerizationExtracellular MatrixHypercholesterolemiaLightPeptidesSwineTissue ScaffoldsCross-Linking ReagentsPeptidesextracellular matrixnatural vascular scaffoldingphotoactivated linkingvascular wall

Identifiers

PMID35054866
PMCPMC8775700
OpenAlexW4205567333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.